Alnylam Pharmaceuticals traded at $145.85 this Thursday June 30th, increasing $0.42 or 0.29 percent since the previous trading session. Looking back, over the last four weeks, Alnylam Pharmaceuticals gained 15.94 percent. Over the last 12 months, its price fell by 14.08 percent. Looking ahead, we forecast Alnylam Pharmaceuticals to be priced at 143.53 by the end of this quarter and at 132.26 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,784.00 -34.00 -0.89% 0.83%
Acadia Pharmaceuticals 14.09 -0.13 -0.91% -43.12%
Agios Pharmaceuticals 22.17 -0.21 -0.94% -60.71%
Alnylam Pharmaceuticals 145.85 0.42 0.29% -14.08%
Amgen 243.30 -2.13 -0.87% -1.46%
Arrowhead Research 35.21 0.65 1.88% -58.56%
Avrobio Inc 0.92 -0.09 -8.91% -90.09%
BioCryst Pharmaceuticals 10.58 -0.23 -2.13% -34.97%
Bluebird Bio 4.14 -0.44 -9.61% -87.23%
BioMarin Pharmaceutical 82.87 -1.05 -1.25% -1.24%
Intercept Pharmaceuticals 13.81 0.14 1.02% -32.54%
Incyte Corp 75.97 0.08 0.11% -9.58%
Ionis Pharmaceuticals 37.02 -0.54 -1.44% -7.57%
Moderna Inc 142.85 0.04 0.03% -39.24%
Mirati Therapeutics 67.13 -0.11 -0.16% -59.67%
Neurocrine Biosciences 97.48 -0.98 -1.00% 0.02%
Novartis 84.53 -0.24 -0.28% -7.77%
PTC Therapeutics 40.06 -0.34 -0.84% -8.46%
Ultragenyx Pharmaceutical 59.66 -0.58 -0.96% -36.61%
Regeneron Pharmaceuticals 591.13 -6.49 -1.09% 1.28%
Regulus Therapeutics 2.07 -0.03 -1.43% 150.76%
Sangamo BioSciences 4.14 0 0% -65.53%
Sanofi 50.03 -2.64 -5.01% -4.81%
Sarepta Therapeutics 74.96 -2.11 -2.74% -4.23%
Vertex Pharmaceuticals 281.79 1.44 0.51% 39.36%
Xencor 27.37 0.17 0.63% -23.29%

Indexes Price Day Year
USND 11029 -149.16 -1.33% -24.06%

Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.